Project Grant R01CA311189
Award Date 9/3/26
Completion Date 8/31/31
Dollars Obligated $665K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
- This five-year, $536,955 project grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Detection and Diagnosis Research program. The Washington University will develop pre-treatment and recurrence biomarkers for locally advanced cervical cancer by analyzing variance in human papillomavirus genomic structures among patient tumors. Researchers will extract HPV genomic features from matched DNA and RNA sequencing data to...
- The National Cancer Institute awarded The University of Chicago $692,063 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to advance early colorectal cancer diagnosis and risk stratification using DNA methylation markers. The funded work develops blood-based biomarkers to detect colorectal cancer and advanced adenomas through cell-free DNA analysis, addressing the gap in sensitivity of existing tools such as MSEPT9, Cologuard, and Shield. The research...
- Federal Grant Award Summary The National Cancer Institute awarded a $371,161 Project Grant to the University of Colorado-Denver under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on September 1, 2025, for a two-year performance period concluding August 31, 2027. The award funds the development of artificial intelligence (AI) algorithms designed to improve cervical cancer screening in low-resource settings. Specifically, the project will create advanced AI risk stratification...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $224,863 to the University of Illinois on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop chemical membrane labeling and fluorescence-guided sequencing technologies to decode microvesicle-mediated cell-cell communication. The award funds development of molecular analysis technologies to address gaps in understanding how...
- The National Cancer Institute awarded the University of California, Los Angeles $446,900 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to optimize geographic expansion of cervical cancer screening and treatment in remote and rural settings. The recipient will develop a scientific framework to identify optimal strategies for expanding cervical cancer screening access under resource constraints, designed to assist the Indian Health Service, the Alaska...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Illinois a $386,279 Project Grant on July 10, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop innovative immunotherapy screening capabilities. The grant funds the creation of a microfluidic device cassette and associated functional immune assay protocols designed to enable personalized immunotherapy screening directly on core needle biopsies from cancer patients. This...
- The National Cancer Institute awarded University of Connecticut Health Center $414,585 on May 6, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate a programmable enzyme-assisted mutation sequencing (PEAM-SEQ) diagnostic platform for detecting cell-free DNA mutations in blood samples to enable noninvasive, early detection of lung cancer. The project will advance a PCR-based PEAM-SEQ V1.0 assay into a simplified PEAM-SEQ V2.0 assay by combining...
- The National Cancer Institute awarded New York University $703,227 on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an ultra-rapid droplet digital PCR method for real-time molecular profiling of cancer-driving mutations during surgical resection. The funded work aims to engineer a microfluidic device that automates ultra-rapid DNA extraction and PCR thermal cycling to profile tissue samples in minutes rather than hours, enabling surgeons to...
- The National Cancer Institute awarded Massachusetts Eye and Ear Infirmary $642,406 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on June 1, 2026, for research on blood-based early detection of viral precancers. The project, titled "Blood-Based Early Detection of Viral Precancers," develops liquid biopsy screening methods to detect cancers at their inception by targeting viral cell-free DNA. Current liquid biopsy approaches that detect mutated or methylated...
- The National Cancer Institute awarded the University of Illinois at Chicago $286,638 under a K08 Mentored Clinical Scientist Research Career Development Award on May 15, 2026, to design and develop an intervention addressing delays in follow-up care after abnormal cervical cancer screening tests in uninsured patients served by safety-net health systems. The research uses a convergent mixed-methods approach to evaluate follow-up care delays and identify patient-, provider-, and system-level...